TABLE 1.
Early-stage survival of uterine sarcomas
Variable | Year published | Stage | n | Survival outcome |
---|---|---|---|---|
Leiomyosarcoma | ||||
Kapp et al3 | 2008 | I | 951 | 5-yr DSS = 75.8% |
II | 43 | 5-yr DSS = 60.1% | ||
Abeler et al4 | 2009 | I | 193 | 5-yr OS = 51% |
II | 36 | 5-yr OS = 25% | ||
Endometrial stromal sarcoma | ||||
Chan et al5 | 2008 | I–II | 540 | 6-yr DSS = 89% |
Abeler et al4 | 2009 | I | 56 | 5-yr OS = 84% |
II | 21 | 5-yr OS = 62% | ||
Adenosarcoma | ||||
Arend et al6 | 2010 | I | 327 | 5-yr OS = 79% |
Undifferentiated uterine sarcoma | ||||
Abeler et al4 | 2009 | I | 14 | 5-yr OS = 57% |
II | 5 | 5-yr OS = 0% | ||
Tanner et al7 | 2012 | I | 7 | Median OS = 26.8 mo |
DSS, disease specific survival; OS, overall survival.
Liu. Critical assessment of morcellation. Am J Obstet Gynecol 2015.